NewAmsterdam Pharma Company NAMS Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's change in accrued liabilities?
- NewAmsterdam Pharma Company (NAMS) reported change in accrued liabilities of -$10.33M in Q1 2026.
- How has NewAmsterdam Pharma Company's change in accrued liabilities changed year-over-year?
- NewAmsterdam Pharma Company's change in accrued liabilities decreased by 108.6% year-over-year, from -$4.95M to -$10.33M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.